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Abstract Most cancer deaths are due to the development
of metastases. Increased expression of RhoC is linked to
enhanced metastatic potential in multiple cancers. Conse-
quently, the RhoC protein is an attractive target for drug
design. The clinical application of immunotherapy against
cancer is rapidly moving forward in multiple areas, includ-
ing the adoptive transfer of anti-tumor-reactive T cells and
the use of “therapeutic” vaccines. The over-expression of
RhoC in cancer and the fact that immune escape by down
regulation or loss of expression of this protein would
reduce the morbidity and mortality of cancer makes RhoC a
very attractive target for anti-cancer immunotherapy.
Herein, we describe an HLA-A3 restricted epitope from
RhoC, which is recognized by cytotoxic T cells. Moreover,
RhoC-speciWc T cells show cytotoxic potential against
HLA-matched cancer cells of diVerent origin. Thus, RhoC
may serve as an important and widely applicable target for
anti-cancer immunotherapeutic strategies.
Introduction
There is consensus that cancer cells are antigenic since they
express tumor-associated antigens that are recognized by
autologous T cells. Several lines of evidence suggest that T
cells are the main eVectors in the immunological response
against cancer cells [12]. Importantly, many T cell antigens
are known to elicit spontaneous reactivity. More than 200
class I-restricted cytotoxic T-lymphocyte (CTL) peptide epi-
topes have been characterized, from highly diverse groups
of proteins, e.g., Muc-1, telomerase, the MAGE proteins,
NY-ESO-1, and p53, etc. [20]. Due to the phenomenon of
“immune escape”, in which antigen-negative cancer cells
avoid immune recognition, strategies have been developed
that conceptually focus on minimizing the risk of immune
escape, by speciWcally targeting proteins that are important
for the function, survival and growth of cancer cells [30].
Thus, it is well established that molecular events lead to the
general cancer traits, e.g., the capacity to uncontrolled
growth (abnormal cell cycle regulation), resistance to death
(apoptosis resistance), the potential to migrate and grow at
distant sites (metastasis), the capacity to induce new blood
vessels (attract endothelial cells), and also the mechanisms
involved in suppression of the immune system by cancer
cells (secretion of immune-suppressive mediators), etc. [14].
The proteins or protein patterns responsible for these charac-
teristics of cancer cells represent ideally suited target struc-
tures for therapeutic intervention, including immunological
targeting. Importantly, these traits—molecular mechanisms
aside—are essential characteristics of all life-threatening
cancers, and therapies based on targeting of these character-
istics molecularly are therefore broadly applicable to most if
not all cancers. Several proteins responsible for or associated
with these cancer traits have been characterized, which are
targets for immunological recognition e.g., cell division (tel-
omerase [31], survivin [4]), resistance to apoptosis (survivin,
Bcl-2, Bcl-X(L), and Mcl-1 [1]), and tumor development
(Cyp1B1 [18]). Recently, heparanase, a protein with metas-
tasis promoting potential was described to be a target for T
cells in cancer patients [29]. Generally, these targets repre-
sent broadly applicable vaccination targets in therapeutic
vaccinations against cancer. Moreover, although vaccination
against these proteins or groups of proteins is in itself a
L. Wenandy · R. B. Sørensen · I. M. Svane · P. thor Straten · 
M. H. Andersen (&)
Center for Cancer Immune therapy (CCIT), 
Department of Hematology, Herlev University Hospital, 
2730 Herlev, Denmark
e-mail: mahaan01@heh.regionh.dk123
1872 Cancer Immunol Immunother (2008) 57:1871–1878promising new approach to Wght cancer, the combination
with additional therapy could create a number of synergistic
eVects.
Rho GTPases aVect several aspects of growth control,
and cytoskeletal organization in response to extracellular
factors [32]. Three Rho family members exist in humans;
RhoA, B and C, which are highly homologous but with
extensive heterogeneity in the C-terminal of the sequence.
Although RhoB and RhoC were characterized at the same
time as RhoA, they have received less attention because
of their extensive homology to RhoA and because over-
expression studies indicated that, like RhoA, they induced
stress Wbers in cells. More recent data suggests a more
diVerential role in that RhoC has been shown to play an
important role in metastasizing cancer cells [11]. Thus, sev-
eral lines of evidence demonstrate a high expression of
RhoC in cancer cells, and that the metastatic potential of
cancer cells depends on expression of RhoC. Selective
increased expression of RhoC has been described in meta-
static cancers. Microarray analysis has shown that expres-
sion of RhoC is progressively increased as tumors become
more aggressively metastatic and RhoC expression pro-
motes metastasis [23, 33]. It has been demonstrated that loss
of RhoC does not aVect tumor development but decreases
tumor cell motility and metastatic cell survival leading to a
drastic inhibition of metastasis [13]. Interestingly, RhoC has
not been found mutated in cancers, indicating that upregu-
lated expression is suYcient to contribute to metastasis. In
the present study, we examined whether RhoC is a target for
cytotoxic T cells in patients with metastatic cancer.
Materials and methods
Patients
Peripheral blood lymphocytes (PBL) from HLA-A3+ can-
cer patients or peripheral blood mononuclear cells (PBMC)
from healthy controls were obtained from the University
Hospital Herlev, Denmark. The cancer patients included all
had histological proven metastastic melanoma or renal cell
carcinoma in progression. Generally, they were in a late
disease stage with no further standard treatment options
available. Cells were cryopreserved in FCS with 10%
DMSO. Tissue typing was conducted at the Department of
Clinical Immunology, The State Hospital, Copenhagen,
Denmark. Informed consent was obtained from the patients
before any of these measures.
RT-PCR for the detection of RhoC transcripts
RNA was extracted using the Purescript Isolation Kit
(Gentra Systems Inc. MN, USA). In brief, 2–5 g of RNA
were used in the synthesis of cDNA using the SuperScript
II reverse transcriptase in a total volume of 50 l 1£ buVer
(Gibco-BRL, Life Technologies Inc., Gaithersburg, MD,
USA) containing 10 mM DTT. The RT reactions were
primed with a mixture of oligo-dT and random hexamers,
and incubations were performed at 37°C for 30 min, 42°C
for 30 min, and 72°C for 5 min. AmpliWcation was carried
out with primers speciWc for RhoC (anti-sense: RhoC: 5-
cggggctagaaaacaatgc-3) together with a common sense
primer (5-ttttccatcgacagccctg-3). The size of the products
is 477 bases. The following cancer cell lines were analyzed:
the melanoma cell lines Est007 (FM3), Est027 (FM82),
Est030 (FM9) (from the IPD-ESTDAB database, available
at http://www.ebi.ac.uk/cgi-bin/ipd/estdab/ [22]), the head
and neck cancer cell line CRL2095, the breast cancer cell
line BT20, and the colon cancer cell line HT29 (from
ATCC, available at http://www.ATCC.org).
Assembly assay for peptide binding to MHC class I 
molecules
The binding aYnity of the synthetic peptides (Genscript,
Scotch Plains, USA) to HLA-A3 molecules was measured
by means of the assembly assay as previously described
[8]. BrieXy, T2–A3 cells were incubated in methionine-free
RPMI 1640 (Gibco BRL, Paisley, UK) with 10% dialysed
FCS. Subsequently, cells were metabolically labeled with
50  Ci 35S-methionine (Amersham, Birkeroed, Denmark).
Cell nuclei were removed by ultracentrifugation. Stably
folded HLA molecules were immune-precipitated using the
HLA class I-speciWc, conformation-dependent mAb W6/
32. A-Sepharose beads were added to collect the folded
MHC complexes and separated by isoelectric focusing gel
electrophoresis. MHC heavy chains were quantiWed using
the ImageGauge Phosphorimager program (FUJI Photo
Film). The intensity of the band is directly related to the
amount of peptide-bound class I MHC complex recovered
during the assay. Subsequently, the extent of stabilization
of HLA-A3 is directly related to the binding aYnity of the
added peptide.
Interferon- (IFN-) ELISPOT assay
The ELISPOT assay was used to quantify peptide epitope-
speciWc IFN- releasing eVector cells as described previ-
ously [5]. To extend the sensitivity of the ELISPOT assay,
PBMCs were peptide stimulated (10 M) once in vitro. Next
day, 40U/ml IL-2 (PeproTech, London, UK) was added.
After 7 days, the cells were tested for reactivity. BrieXy,
nitrocellulose bottomed 96-well plates (MultiScreen MAIP
N45; Millipore, Glostrup, Denmark) were coated with anti-
IFN- Ab (1-D1 K; Mabtech, Nacka, Sweden). The wells
were washed, blocked by X-vivo medium and the eVector123
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without 10 M peptide (Rho1L2: RLGLQVRKNK; Rho1:
RAGLQVRKNK) together with 104 T2–A3 cells. The plates
were incubated overnight. The following day, medium was
discarded and the wells were washed prior to addition of
biotinylated secondary Ab (7-B6-1-Biotin; Mabtech, Nacka,
Sweden). The plates were incubated at room temperature
(RT) for 2 h, washed, and avidin–enzyme conjugate (AP-
Avidin; Calbiochem/Invitrogen Life Technologies) was
added to each well. Plates were incubated at RT for 1 h and
the enzyme substrate NBT/BCIP (Invitrogen Life Technolo-
gies) was added to each well and incubated at RT for 5–
10 min. The reaction was terminated with tap-water upon
the emergency of dark purple spots. The spots were counted
using the ImmunoSpot® Series 2.0 Analyzer (CTL Analyz-
ers, LLC, Cleveland, USA) and the peptide-speciWc CTL
frequency could be calculated from the numbers of spot-
forming cells. The number of antigen-speciWc spots was
calculated by subtracting the mean number of spots of the
control wells from the mean number of spots in the positive
wells; responses with a P value <0.05 (Student’s t test for
unpaired samples) were considered as positive. The deWni-
tion is in respect with the CIMT Monitoring Panel inter-lab-
oratory testing project (http://www.c-imt.org) [10].
Dendritic cells
Dendritic cells (DC) were generated from PBMC by adher-
ence on culture dishes at 37°C/5% CO2 for 60 min in
RPMI-1640 enriched with 10% human AB serum. Adher-
ent monocytes were cultured in RPMI-1640 supplemented
with 10% human AB serum in the presence of IL-4 (250 U/
ml) and GM–CSF (1,000 U/ml) (Leucomax, Shering
Plough, Farum, Denmark) for 6 days. DC were matured
by addition of IL-1 (10 ng/ml), IL-6 (10 ng/ml), TNF-
(10 ng/ml) (CellGenix, Freiburg, Germany), and PGE2
(1 g/ml) (PWzer, Brussels, Belgium).
Establishment of antigen-speciWc T cell cultures and clones
PBL from an untreated 65-year-old melanoma (MM) patient
with multiple liver metastases, left pleural tumor, eVusion,
and osteolytic bone metastases were used for analyses. He
had not received any treatment for his disease. PBL were
stimulated with irradiated (20 Gy) autologous Rho1L2-
loaded DC (PBL:DC ratio = 3 £ 106:3 £ 105). The follow-
ing day IL-7 (5 ng/ml) and IL-12 (10 ng/ml) (PeproTech,
London, UK) were added. Stimulation of the cultures were
carried out every 10 days with Rho1L2-loaded irradiated
autologous DC (2£) followed by Rho1L2-loaded irradiated
autologous PBL (3£). One hundred and twenty U/ml IL-2
(PeproTech, London, UK) was added after each stimulation.
Growing cultures were tested for speciWcity for Rho1L2.
PBL from a speciWc culture were cloned by limiting
dilution in the presence of cloning mix containing 106/ml
irradiated (20 Gy) lymphocytes from three healthy donors
in X-vivo with 5% heat-inactivated human serum, 25 mM
HEPES buVer (GibcoBRL, Paisley, UK), and 120 U/ml IL-2
(PeproTech, London, UK). The plates were incubated at
37°C/5% CO2. Every 3–4 days 50 l fresh media were
added containing 120 M/ml IL-2. Growing clones were
expanded using cloning mix cells (5 £ 104 cells/well) and
IL-2. After expansion the clones were tested for speciWcity
and cytotoxic potential in a standard 51Cr-release assay.
Cytotoxicity assay
Conventional 51Cr-release assays for CTL-mediated cyto-
toxicity were carried out as described elsewhere [2]. Target
cells were T2–A3 cells, the HLA-A3+ breast cancer cell
line BT-20, the HLA-A3+ colon cancer cell line HT-29,
the HLA-A3+ head and neck cancer cell line CRL-2095
(all available at the American Type Culture Collection
(ATCC)), the HLA-A3+ melanoma cell line FM9, the
HLA-A3- melanoma cell line FM82, and the HLA-A3+
melanoma cell line FM3 [15], with or without added HLA
speciWc mAb W6/32 [7] (2 g/100 l [27]) or the HLA-A3
speciWc antibody GAPA3 [28].
Results
HLA-A3 binding peptides from RhoC
RhoC mainly diVers from RhoA and RhoB in the C-termi-
nal part of the sequence. Hence, this 20 amino acid region
was scrutinized for putative HLA epitopes using the main
HLA-speciWc anchor residues [6]. We identiWed a possible
HLA-A3-restricted peptide Rho1 (RAGLQVRKNK).
However, as Alanine is a poor anchor amino acid in posi-
tion 2 this peptide was only expected to bind to HLA-A3
with low aYnity. As many of the established T cell epitopes
presented by cancer cells such as the melanoma antigens
gp100 and MART-1 have relatively low binding aYnities
to the respective HLA class I molecules, it is common
practice to generate heteroclitic peptides from such low-
aYnity epitopes by substitution of amino acids at speciWc
positions, i.e., the anchor positions, which are crucial for
the binding of the peptide to the HLA molecule [21, 26].
Consequently, we included a modiWed counterpart Rho1L2
(RLGLQVRKNK) in our studies, in which position 2 was
modiWed from Alanine to Leucine. The two peptides were
synthesized and examined for binding to HLA-A3 by com-
parison with the HLA-A3 high aYnity positive control
epitope from InXuenza NP265–273 (ILRGSVAHK) by the
assembly assay (data not shown). The modiWed Rho1L2123
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value t 4 m), whereas the native peptide Rho1 only
bound very weakly to HLA-A3 (C50-value > 40 m) com-
pared to a positive control peptide from InXuenza NP265–273
(C50-value t 0.5 m).
Spontaneous T cell responses towards RhoC
We scrutinized PBL from HLA-A3+ MM and renal cell
carcinoma (RCC) patients for the presence of speciWc T cell
responses against the modiWed Rho1L2 (RLGLQVRKNK)
peptide by means of the IFN- ELISPOT secretion assay.
As depicted in Fig. 1, speciWc T cell responses were present
among PBL of three out of ten MM patients. However, we
could not detect a response against the very weak HLA-A3-
binding native peptide in these patients (data not shown).
Likewise, no responses were detected in either RCC
patients or healthy controls (HD) against either Rho1L2 or
Rho1.
T cell antigen speciWcity and Rho1/Rho1L2 cross-reactivity
Having identiWed patients hosting responses against the
Rho1L2 peptide, we used PBL from these cancer patients
to generate CTL bulk cultures against this peptide in vitro.
Subsequently, we in vitro stimulated PBL from such a
patient with Rho1L2-pulsed autologous DC. After Wve in
vitro restimulations, the peptide speciWcity was tested in
standard 51Cr release assays using T2–A3 cells without
peptide or loaded with Rho1 (10 M) or Rho1L2 (10 M)
as target cells (Fig. 2a). This assay revealed that the bulk
cultures lysed both T2–A3 cells pulsed with Rho1L2 and
Rho1 eYciently, whereas no cytotoxicity was observed
against unpulsed T2–A3 cells.
Next, CTL clones were established from the speciWc T
cell cultures by limiting dilution. After a short expansion
step, the speciWcity of the growing clones was analyzed in
standard 51Cr release assays. Four RhoC-speciWc T cell
clones were generated, and one of these was selected for
further expansion as it had the highest growth rate (# clone
9). Clone 9 eVectively lysed T2-A3 cells pulsed with both
the modiWed Rho1L2 and the native Rho1 peptide underlin-
ing that Rho1L2 speciWc T cells cross react with the native
analog peptide (Fig. 2b). To examine the HLA restriction of
clone 9, we tested the eVect of blocking HLA-class I by
addition of the HLA speciWc mAb W6/32 and the HLA-A3
speciWc mAb GAP A3. Lysis could be completely blocked
by incubation of the target cells with both antibodies
(Fig. 2b).
Capacity of RhoC-speciWc T cells to kill tumor cells
We examined RhoC expression in cancer cells of diVerent
origin by RT-PCR. All cancer cell lines examined expressed
RhoC (Fig. 3). Next, we examined the Rho1L2/Rho1 spe-
ciWc bulk cultures capacity to kill RhoC+ melanoma cells.
Fig. 1 HLA-A3 restricted T-cell responses against Rho1L2 as
measured by IFN- ELISPOT The average number of peptide speciWc
IFN- spots formed in response to Rho1L2 among 5 £ 105 in vitro
stimulated PBMC from Wve HLA-A3+ healthy donors (HD), PBL
from ten renal cell carcinoma patients (RCC), and ten melanoma


























Fig. 2 T cell antigen speciWcity and cross reactivity. a Cytotoxicity by
51Cr-release assay of a bulk culture stimulated with Rho1L2-loaded
autologous DC/autologous PBL. SpeciWc lysis of T2-A3 cells with no
peptide or pulsed with Rho1L2 (10 M) or Rho1 (10 M). E:T ratio =
60:1, 30:1. b SpeciWcity of a T cell clone (clone 9) assayed by 51Cr-
release assay. Lysis of T2-A3 cells with no peptide, pulsed with
Rho1L2 (10 M), Rho1 (10 M) and of Rho1L2-pulsed T2–A3 cells
with addition of the HLA-class I speciWc antibody W6/32 or HLA-A3
speciWc antibody GAP A3 at diVerent E:T ratios (9:1; 3:1; 1:1; 0,3:1).
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killed with high eYcacy in a HLA-restricted matter as lysis
could be completely blocked by incubation of FM3 target
cells with W6/32 (Fig. 4a).
Likewise clone 9 generated from the speciWc bulk culture
was able to kill FM3 melanoma cells (Fig. 4b). A second
experiment conWrmed the aforementioned results (Fig. 4c).
The addition of cold (unlabeled) T2-A3 cells pulsed with the
Rho1L2 (10 M) peptide completely abrogated the killing
of FM3 melanoma cells (Fig. 4b, c). Moreover, the RhoC-
speciWc CTL clone was able to lyse the HLA-A3+ mela-
noma cancer cell line FM9. As an additional control, we
used the HLA-A3- melanoma cell line FM82 as target cells.
No cytotoxicity was observed against this cell line.
As the expression of RhoC in metastatic cancer has been
described in cancers of diVerent origin we further examined
the RhoC speciWc CTL clone capacity to kill other cancer
cells than melanoma (Fig. 4d). Subsequently, the HLA-
A3+ breast cancer cell line BT-20, the HLA-A3+ head and
neck cancer cell line CRL-2095 and the HLA-A3+ colon
cell line HT-29 were used as target cells. The RhoC-spe-
ciWc CTL clone lysed all HLA-A3+ cell lines, although the
colon cell line HT-29 only to a limited extent.
Discussion
RhoC has been identiWed as an especially important player
in metastasis [11, 13], and its expression correlates with
metastatic spread of various types of carcinomas [16, 17].
Ideal targets for immunotherapy are gene products silenced
in normal tissues but over-expressed in cancer cells, and
directly involved in tumor cell survival and progression.
Metastasis is the culmination of neoplastic progression. The
important role of a given protein in the process of metasta-
sizing implies that immune escape by down regulation or
loss of expression of this protein would reduce the morbid-
ity and mortality of cancer. These characteristics highlight
RhoC as a very attractive target for immunotherapy of
Fig. 3 PCR products electrophoresed in agarose gel and stained with
EtBr. The image represents Wve diVerent cancer cell lines, all being
positive for RhoC. For each cancer cell line the left band represents
GAPDH and the right band represents RhoC
Fig. 4 Functional capacity of RhoC-speciWc T cells. a Cytotoxicity of
a bulk culture stimulated with Rho1L2-loaded autologous DC/autolo-
gous PBL. SpeciWc lysis of the HLA-A3+ melanoma cell line FM3
without and with the addition of the HLA-class I speciWc antibody W6/
32. E:T ratio = 60:1, 40:1. b Lysis by a Rho1L2-speciWc clone (clone
9) of the HLA-A3+ melanoma cell line FM3, cell lysis with addition of
unlabeled T2-A3 cells pulsed with Rho1L2 (10 M) or no peptide
(inhibitor to target ratio = 20:1), and cell lysis of the HLA-A3+ mela-
noma cell line FM9 and the HLA-A3- melanoma cell line FM82. Mea-
surements were made in duplicates for all E:T ratios. c Repetition of
the experiments shown in b) (without inclusion of FM9). d Lysis by a
Rho1L2-speciWc clone of the HLA-A3+ breast cancer cell line BT-20,
colon cancer cell line HT-29 and head and neck cancer cell line CRL-
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of RhoC has been described in metastatic cancers, the intro-
duction of T cell tolerance against RhoC might be less
problematic compared to tumor antigens, which are
expressed in the primary tumor at high levels.
To sustain the hypothesis of RhoC as a broadly
expressed T cell target we initially followed a ‘reverse
immunology’ approach. We scanned the C-terminal region
of the RhoC protein for the presence of HLA-A3 peptide
binding motifs and used these to search for speciWc T cell
responses in cancer patients. To this end, we were able to
detect spontaneous HLA-A3-restricted CTL responses
against a modiWed RhoC peptide epitope by means of ELI-
SPOT in PBL from melanoma patients. No responses
against this modiWed epitope were detected in any healthy
controls. However, we could not detect a response in the
ELISPOT against the native low-aYnity binding peptide in
PBL from neither cancer patients nor healthy controls. It
has previously been described that it is possible to measure
spontaneous T cell responses against modiWed peptides in
PBL of cancer patients by the ELISPOT without detectable
responses against the native analogs. This is largely due to
technical reasons, e.g., stabilization of suYcient amounts of
class I molecules on the surface of the T2 cells [3, 9]. A bet-
ter place to look for speciWc T cells would be in the inXam-
matory inWltrate of the tumor or in the bone marrow. With
regard to the latter, Sommerfeldt and colleagues show very
strong T cell responses against heparanase in the bone mar-
row of cancer patients [29].
The use of modiWed peptides with improved HLA bind-
ing aYnities has previously been demonstrated to be suit-
able for induction of CTL responses [25]. It is, however,
still critical to establish that Rho1L2-speciWc CTL also
react against the native Rho1 peptide. Hence, a critical
issue in the reverse immunology strategy for CD8 T cell
target antigen identiWcation is clearly to demonstrate that
the peptide is processed and naturally presented on the sur-
face of tumor cells. In order to do so we in vitro stimulated
PBL from a responding patient with the Rho1L2 peptide
and showed that the resulting culture was able to kill not
only target cells pulsed with the modiWed peptide, but in
addition both target cells pulsed with the native peptide and
melanoma cells. To further clarify this point, we cloned
RhoC-speciWc T cells and examined the speciWcity and
immunogenicity of such CD8 T cells. The Rho1L2 speciWc
clone not only killed target cells pulsed with the modiWed
peptide Rho1L2 but in addition recognized the native Rho1
peptide in an antigen speciWc and HLA-A3-restricted man-
ner. Furthermore, it eVectively killed cancer cell lines of
diVerent origin in a HLA-restricted manner. Consequently,
the presentation of the Rho1 peptide in context of HLA-A3
molecules on the tumor cells is necessary for the eYcient
lysis of target cells. The killing of tumor cells of diVerent
origin underlines the universal characteristics of RhoC. The
HLA-A3 restriction of the clone was conWrmed using
monoclonal antibodies and cold target cells (peptide pulsed
T2-A3 cells), which completely abrogated killing of tumor
cells. Any potential correlation between CTL lysis and
RhoC expression would be extremely revealing especially
since microarray analysis has shown that expression of
RhoC in vivo is progressively increased as tumors become
more aggressively metastatic. We could, however, not
detect a direct correlation between RhoC expression and
lysis as the RhoC expression in the cell line HT-29 (which
is relatively poorly killed by the RhoC-speciWc T cells) is as
high as in any of the other lines. In this regard, it should be
noted that many factors contribute to the killing (or lack of
killing) of target cells by cytotoxic T cells, including T cell
avidity, expression of HLA on the surface of the target cells
as well as inhibitory and/or activating co-receptors.
RhoA, RhoB, and RhoC are highly homogeneous shar-
ing 85% amino acid sequence. As we wanted to examine
the T cell reactivity against RhoC we examined the C-ter-
minal region of RhoC as this region completely diVers from
RhoA and RhoB (no homology). However, this region only
includes around 20 amino acids, which implies that it might
not include peptide epitopes restricted to all class I and/or II
alleles. Naturally, there might be other regions of RhoC
from which there are derived peptides that are recognized
by T cells. Such T cells might, however, in addition recog-
nize RhoA and RhoB derived peptides. Consequently, a
potential anti-cancer response directed against such pep-
tides could lead to a response against the non-relevant pro-
teins RhoA and especially RhoB. However, although the
main concern in anti-cancer immune therapy is severe auto-
immunity, it only represents one side of the story. Another
important aspect is the fact that a T cell response against
peptides from other regions of RhoC would be opposed by
mechanisms regulating and suppressing immunity against
RhoA and RhoB. Thus, T cell tolerance caused by cross-
reactivity with RhoA and RhoB could reduce the anti-
cancer response.
Harnessing of the immune system for the battle against
cancer has been the focus of tremendous research eVorts
over the past two decades. Multiple means to achieve this
goal have been investigated, including adoptive transfer
of anti-tumor-reactive T cells, and systemic or localized
administration of immune modulating cytokines. Clinical
vaccination trials using tumor-associated antigen-derived
peptides are presently ongoing and although most cancer
patients included in current vaccination trials are end-stage
patients, vaccination has repeatedly been shown to be capa-
ble of induction of anti-tumor CTL responses [19, 24]. Still,
the clinical beneWt for the treated patients is only marginal.
We believe that induction of powerful T cell responses
against RhoC, e.g., by therapeutic vaccination, may oVer a123
Cancer Immunol Immunother (2008) 57:1871–1878 1877new mean to target metastatic cancer cells. This would be
particularly attractive after surgery of the primary tumor as
selective increased expression of RhoC has been described
in metastatic cancers. Naturally this needs to be veriWed,
e.g., by the use of animal studies, to determine vaccination
time, dose and indication(s) before moving into the clinic.
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